Table 4.

OS for patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (ITT population as of July 7, 2023)

Variable	Dostarlimab + chemotherapy (N = 121)	Pembrolizumab + chemotherapy (N = 122)
Median OS follow-up time, months (IQR)	20.7 (17.3–24.0)	21.6 (18.3–24.1)
OS events observed, n	59	75
Median OS (95% CI), months	19.4 (14.5–NR)	15.9 (11.6–19.3)
Estimated probability of OS, % (95% CI)
6 months	76 (67–83)	78 (69–84)
12 months	63 (54–71)	58 (48–66)
Hazard ratio (95% CI)	0.75 (0.53–1.05)

CI confidence interval, IQR interquartile range, ITT intention-to-treat, NR not reached, OS overall survival.